Biosimilars

Five things for pharma marketers to know: Friday, March 10, 2017

Five things for pharma marketers to know: Friday, March 10, 2017

By

Novartis' Gleevec shows long-term survival benefit in study; Novo Nordisk CEO considers small acquisitions; Merck KGaA to sell biosimilars unit

Five things for pharma marketers to know: Wednesday, February 15, 2017

Five things for pharma marketers to know: Wednesday, February 15, 2017

By

Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto

Five things for pharma marketers to know: Wednesday, January 18, 2017

Five things for pharma marketers to know: Wednesday, January 18, 2017

By

Rep. Price to answer questions at confirmation hearing; 22 drugmakers invest in fighting disease in poor countries; FDA approves generic of Jazz's Xyrem

 Five things for pharma marketers to know: Friday, January 13, 2017

Five things for pharma marketers to know: Friday, January 13, 2017

By

CVS to sell generic EpiPen; FDA finalizes biosimilar naming rules; Pfizer wants to make a deal

Five things for pharma marketers to know: Tuesday, October 18, 2016

Five things for pharma marketers to know: Tuesday, October 18, 2016

By

Pfizer to start selling Remicade biosimilar in November; The Medicines Co.'s PCSK9 inhibitor heads to Phase-III trials; J&J's Q3 growth bolstered by autoimmune drugs

Five things for pharma marketers to know: Friday, October 14, 2016

Five things for pharma marketers to know: Friday, October 14, 2016

By

Merck launches biosimilar resource; branded insulin prices are on the rise; NICE declines to cover Opdivo

Five things for pharma marketers to know: Monday, October 3, 2016

Five things for pharma marketers to know: Monday, October 3, 2016

By

More drugmakers file lawsuits to prevent biosimilar competition; experimental dermatitis drug showeds promising results; pharma blames PBMs for price hikes

The FDA approves Amgen's biosimilar version of Humira

The FDA approves Amgen's biosimilar version of Humira

By

Amgen's drug is set to compete with AbbVie's Humira, which is the second-best selling drug in the U.S. in 2015.

Five things for pharma marketers to know: Wednesday, August 31, 2016

Five things for pharma marketers to know: Wednesday, August 31, 2016

By

The FDA approves an Enbrel biosimilar; Express Scripts to launch program to reduce diabetes costs; a GSK vaccine beats sales forecasts

Five things for pharma marketers to know: Thursday, August 18, 2016

Five things for pharma marketers to know: Thursday, August 18, 2016

By

Court clears Pfizer to move ahead with Remicade biosimilar; McDonald's yanks activity trackers over skin irritation; California drug-pricing bill pulled

Five things for pharma marketers to know: Friday, July 22, 2016

Five things for pharma marketers to know: Friday, July 22, 2016

By

Herceptin biosimilar meets endpoint in clinical trial; Roche plans to launch five new drugs over the next year; government seeks to block insurer deals

Five things for pharma marketers to know: Thursday, July 14, 2016

Five things for pharma marketers to know: Thursday, July 14, 2016

By

The FDA expands use for Pfizer's Prevnar 13 vaccine; an FDA panel votes in support of Novartis biosimilar; U.S. healthcare spending rises 5.5% in 2015

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

By

Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.

What do physicians think about biosimilars?

What do physicians think about biosimilars?

By

A Sermo poll asked physicians: Do you feel biosimilars will prove safe and effective enough for you to prescribe them when more become available?"

Five things for pharma marketers to know: Friday, May 6, 2016

Five things for pharma marketers to know: Friday, May 6, 2016

By

Investigation says Oxycontin wears off sooner than it claims; PBMs and insurers anticipate high biosimilar prices; Valeant forms pricing committee

Infographic: the growing biosimilar market in the U.S.

Infographic: the growing biosimilar market in the U.S.

The FDA has approved two biosimilars, but questions remain about how quickly providers and patients in the U.S. will adopt them.

Competition drives down sales of J&J's Olysio

Competition drives down sales of J&J's Olysio

By

The company said growth in its immunology portfolio offset declining Olysio sales.

Five things for pharma marketers to know: Wednesday, April 6, 2016

Five things for pharma marketers to know: Wednesday, April 6, 2016

By

Pfizer and Allergan call off merger; the FDA approves second biosimilar; NEJM comes under fire

Five things for pharma marketers to know: Wednesday, March 30, 2016

Five things for pharma marketers to know: Wednesday, March 30, 2016

By

There are 23 biosimilars ready to file with the FDA; an FDA committee votes in favor of Parkinson's disease drug; Bloomberg funds new immunotherapy center

Five things for pharma marketers to know: Friday, February 12, 2016

Five things for pharma marketers to know: Friday, February 12, 2016

By

Aegerion slashes workforce; GSK president says downward pressure on drug prices is here to stay; Novartis acquires European rights to Remicade biosimilar

With support of FDA committee, Remicade biosimilar edges closer to market

With support of FDA committee, Remicade biosimilar edges closer to market

By

The FDA is set to announce its decision on the drug in April.

Five things for pharma marketers to know: Wednesday, February 10, 2016

Five things for pharma marketers to know: Wednesday, February 10, 2016

By

SEC is investigating Salix Pharmaceuticals; FDA adcomm recommends approval of Remicade biosimilar; Medicare considers payment changes

Five things for pharma marketers to know: Tuesday, February 9, 2016

Five things for pharma marketers to know: Tuesday, February 9, 2016

By

The FDA to review biosimilar Remicade; lawmaker looks at panelists' ties to painkiller manufacturers; Novartis signs risk-sharing contracts for Entresto

Five things for pharma marketers to know: Friday, February 5, 2016

Five things for pharma marketers to know: Friday, February 5, 2016

By

Johnson & Johnson collaborates with biotech on diabetes stem-cell treatment; the FDA warms up to Remicade biosimilar; Woodcock warns about biosimilar backlog

Five things for pharma marketers to know: Thursday, December 17, 2015

Five things for pharma marketers to know: Thursday, December 17, 2015

By

The FDA approves Lilly's Lantus follow-on biologic; AstraZeneca buys majority stake in Acerta Pharma; Shkreli arrested on securities fraud charges

Five things for pharma marketers to know: Wednesday, November 18, 2015

Five things for pharma marketers to know: Wednesday, November 18, 2015

By

Califf defends his past; Drug spending to increase by 4%-7% per year through 2020; Samsung Bioepis's Enbrel biosimilar faces decision-date Friday

Five things for pharma marketers to know: Monday, October 5, 2015

Five things for pharma marketers to know: Monday, October 5, 2015

By

Keytruda approved in non-small cell lung cancer; Enbrel biosimilar inches closer to approval; study finds no link between autism and vaccines

Sandoz: Zarxio marketing to be similar to a branded-drug launch

Sandoz: Zarxio marketing to be similar to a branded-drug launch

By

Sandoz plans to take a branded approach as it launches the first FDA-approved biosimilar product.

Five things for pharma marketers to know: Thursday, September 3, 2015

Five things for pharma marketers to know: Thursday, September 3, 2015

By

Novartis launches Zarxio, the first US biosimilar; UCB sells its generic business; one-third of children with ADHD are diagnosed before they turn six

Judge's ruling allows Sandoz to begin marketing its biosimilar Zarxio

Judge's ruling allows Sandoz to begin marketing its biosimilar Zarxio

By

The motion denied Amgen's bid for a temporary injunction that would have prevented the launch of Zarxio, the first FDA-approved biosimilar and a competitor to Amgen's Neupogen.

OPINION

Gottlieb Likely to Take On Off-Label, Predictability at the FDA

Newsletters